Barclays analyst Peter Lawson initiated coverage of Nurix Therapeutics with an Overweight rating and $20 price target. Nurix is a clinical stage biotechnology company developing novel protein degraders that could change cancer treatment, the analyst tells investors in a research note. The firm sees an attractive valuation for the shares with "value-inflecting" data readouts in in the second half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Nurix Therapeutics initiated with an Outperform at Oppenheimer
- Down More Than 40%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore
- Nurix Therapeutics price target lowered to $31 from $37 at Stifel
- Nurix Therapeutics, Inc. Earnings Report: Did it Beat Expectations?
